U.S. Markets closed

Strength Seen in Pharmacyclics (PCYC): Stock Rises 10.1%

Zacks Equity Research

Pharmacyclics Inc. (PCYC) was a big mover last session, as the company saw its shares increase more than 10% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. This continues the recent uptrend for this drug manufacturer company as the stock is now up nearly 12% in the past one month time frame.

The company has seen 5 positive revisions in the past few weeks and its earnings consensus has moved up over the past two months, suggesting there could be more solid trading down the road for PCYC. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Pharmacyclics currently has a Zacks Rank #2 (Buy) and its Earnings ESP is positive.

Some better performing drug manufacturers include BioSpecifics Technologies Corp. (BSTC), Questcor Pharmaceuticals, Inc. (QCOR) and United Therapeutics Corporation (UTHR). All these carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Read the Full Research Report on UTHRRead the Full Research Report on BSTCRead the Full Research Report on QCORRead the Full Research Report on PCYCZacks Investment Research